EBRO 2017

TROG 01.04 Trans-Tasman Radiation Oncology Group

• 326 patients. T3N0-2 on MRI or US.

• Randomisation – SCRT 25/5 + early surgery + 6# chemo. – LCRT 50.4/28 + 5-FU + delayed surgery + 4# chemo

SCRT LCRT

p value

3-year LR

7.5% 4.4% 0.23

Distal tumours (≤5 cm)

6/48

1/31

0.21

5-year OS

74% 70% 0.62

Late toxicity

5.8% 8.2% 0.53

Ngan SY. J Clin Oncol. 2012;30(31):3827-33